Peps
What is Efpeglenatide?
Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Biological role or research focus
Cardiovascular and kidney outcomes in diabetes.
These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Role reference: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
- Class / identity
- Long-acting exendin-based GLP-1 receptor agonist
- Research focus
- Cardiovascular and kidney outcomes in diabetes
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
How Efpeglenatide works
It stimulates the GLP-1 receptor. The trial connects this receptor-based intervention with clinical events, rather than relying solely on blood-glucose or weight changes.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Clinical context & research status
This article summarizes AMPLITUDE-O, not a worldwide approval determination. Regulatory availability and product identity require their own current references.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2021
AMPLITUDE-O
Did cardiovascular and renal events differ in high-risk diabetes?
- Population / model
- 4,076 adults with type 2 diabetes and cardiovascular disease, or kidney disease plus an additional cardiovascular risk factor.
- Study design
- Randomized placebo-controlled outcomes trial; median follow-up 1.81 years.
- Main finding
- Major cardiovascular events occurred in 7.0% versus 9.2%: hazard ratio 0.73 (95% CI 0.58–0.92). The renal composite occurred in 13.0% versus 18.4%: hazard ratio 0.68.
- Limits & context
- These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. ↗
Cardiovascular diabetology · 2021 Sep 15 · Journal Article, Meta-Analysis, Systematic Review
Read available full text ↗
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. ↗
Journal of the American College of Cardiology · 2025 Nov 18 · Journal Article, Systematic Review, Meta-Analysis
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis. ↗
Diabetes, obesity & metabolism · 2025 Apr · Comparative Study, Journal Article, Network Meta-Analysis, Systematic Review
Effects of GLP-1 receptor agonists on neurological complications of diabetes. ↗
Reviews in endocrine & metabolic disorders · 2023 Aug · Systematic Review, Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Diarrhea, constipation, nausea, vomiting, and bloating were more frequent with efpeglenatide. The trial’s favorable event outcomes do not eliminate tolerability problems or establish safety for unrelated preparations.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Identity, route, and evidence limits
These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Does a kidney composite prove every kidney outcome improved?
- What population, comparator, and route were actually studied?
- These are findings in people with diabetes and elevated risk, not a longevity trial in healthy adults. Composite endpoints must be read with their component definitions. Sanofi funded the study.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does a kidney composite prove every kidney outcome improved?
No. A composite combines several events. Read the original definitions and individual components before assuming a reduction in dialysis, death, or any particular outcome.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. · 2021 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.